{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:19Z","timestamp":1791499279292,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharma Vertrieb GmbH & Co. KG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to describe the cytomegalovirus (CMV) infection rate, rehospitalizations, and comorbidities following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantation (SOT).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who received allo-HSCT or SOT in 01\/07\/2015\u201330\/06\/2018 were identified using anonymized German claims data. The transplantation-related hospital admission date was defined as the index date, and patients were followed for up to 12\u00a0months (or death, first event relevant). The frequency of CMV infections (confirmed outpatient\/inpatient diagnoses, ICD-10-GM codes: B25.-\/B27.1) and the rate, number, and duration of all-cause rehospitalizations in the follow-up period were evaluated.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 226 allo-HSCT and 250 SOT patients were identified (mean age 52.8\u00a0years, 38.9% female). During the 12\u00a0months after transplantation, 29.2% of allo-HSCT patients and 16.8% of SOT patients received a CMV diagnosis. The majority of these diagnoses were given during the initial hospitalization or within the following 3\u00a0months. Across transplantation types, CMV patients had more hospital readmission days per patient-year (allo-HSCT 93.3 vs. 49.4, <jats:italic>p<\/jats:italic>\u2009=\u20090.001; SOT 42.0 vs. 20.7, <jats:italic>p<\/jats:italic>\u2009=\u20090.005), with a longer mean duration of readmissions (allo-HSCT 22.4 vs. 15.4\u00a0days, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; SOT 11.6 vs. 7.5\u00a0days, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Comorbidity burden in transplantation patients was substantial, with several diagnoses being significantly more common among patients with CMV vs. non-CMV. One-year mortality did not differ significantly between patients with\/without CMV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Burden of transplant recipients with CMV in terms of rehospitalizations and comorbidities is substantial, highlighting the need for improved CMV prevention and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-022-01847-2","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T08:33:09Z","timestamp":1653726789000},"page":"1543-1555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-8060","authenticated-orcid":false,"given":"Daniel","family":"Teschner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7879-9287","authenticated-orcid":false,"given":"Jana","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1054-0081","authenticated-orcid":false,"given":"Christian","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-9380","authenticated-orcid":false,"given":"Sophia","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-1301","authenticated-orcid":false,"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"1847_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200267","volume":"13","author":"R Lachmann","year":"2018","unstructured":"Lachmann R, Loenenbach A, Waterboer T, Brenner N, Pawlita M, Michel A, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS One. 2018;13: e0200267. https:\/\/doi.org\/10.1371\/journal.pone.0200267.","journal-title":"PLoS One"},{"key":"1847_CR2","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1086\/508173","volume":"43","author":"SAS Staras","year":"2006","unstructured":"Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988\u20131994. Clin Infect Dis. 2006;43:1143\u201351. https:\/\/doi.org\/10.1086\/508173.","journal-title":"Clin Infect Dis"},{"key":"1847_CR3","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29:e2034. https:\/\/doi.org\/10.1002\/rmv.2034.","journal-title":"Rev Med Virol"},{"key":"1847_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/s1473-3099(04)01202-2","volume":"4","author":"MK Gandhi","year":"2004","unstructured":"Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725\u201338. https:\/\/doi.org\/10.1016\/s1473-3099(04)01202-2.","journal-title":"Lancet Infect Dis"},{"key":"1847_CR5","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","volume":"221","author":"G Haidar","year":"2020","unstructured":"Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221:S23\u201331. https:\/\/doi.org\/10.1093\/infdis\/jiz454.","journal-title":"J Infect Dis"},{"key":"1847_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668.","journal-title":"Clin Infect Dis"},{"key":"1847_CR7","unstructured":"Gesellschaft f\u00fcr Virologie (GfV e.V.) & Deutsche Vereinigung zur Bek\u00e4mpfung der Viruskrankheiten (DVV e.V.). Virusinfektionen bei organ- und allogen stammzell-transplantierten: Diagnostik, pr\u00e4vention und therapie - S2k-Leitlinie AWMF registernummer 093\u2013002. AWMF online; 2019. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/093-002l_S2k_Virusinfektionen-Organtransplantierte-alloge-Stammzell-Transplantierten-Diagnostik-Praevention-Therapie__2019-06.pdf"},{"key":"1847_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12877","volume":"20","author":"RK Avery","year":"2018","unstructured":"Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, et al. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the organ transplant infection prevention and detection study: a multi-year, multicenter prospective cohort study. Transpl Infect Dis. 2018;20: e12877. https:\/\/doi.org\/10.1111\/tid.12877.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","volume":"17","author":"C Robin","year":"2017","unstructured":"Robin C, H\u00e9mery F, Dindorf C, Thillard J, Cabanne L, Redjoul R, et al. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect Dis. 2017;17:747. https:\/\/doi.org\/10.1186\/s12879-017-2854-2.","journal-title":"BMC Infect Dis"},{"key":"1847_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/03007995.2019.1664826","volume":"36","author":"J Schelfhout","year":"2020","unstructured":"Schelfhout J, Bonafede M, Cappell K, Cole AL, Manjelievskaia J, Raval AD. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36:33\u201341. https:\/\/doi.org\/10.1080\/03007995.2019.1664826.","journal-title":"Curr Med Res Opin"},{"key":"1847_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","volume":"45","author":"P Ramanan","year":"2013","unstructured":"Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45:260\u201371.","journal-title":"Infect Chemother"},{"key":"1847_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jmv.23539","volume":"85","author":"H Harvala","year":"2013","unstructured":"Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85:893\u20138. https:\/\/doi.org\/10.1002\/jmv.23539.","journal-title":"J Med Virol"},{"key":"1847_CR13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/ajt.12388","volume":"13","author":"O Manuel","year":"2013","unstructured":"Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402\u201310. https:\/\/doi.org\/10.1111\/ajt.12388.","journal-title":"Am J Transplant"},{"key":"1847_CR14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.transproceed.2007.07.039","volume":"39","author":"C Cervera","year":"2007","unstructured":"Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Ant\u00f3n A, et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc. 2007;39:2228\u201330. https:\/\/doi.org\/10.1016\/j.transproceed.2007.07.039.","journal-title":"Transplant Proc"},{"key":"1847_CR15","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.transproceed.2011.05.007","volume":"43","author":"L Linares","year":"2011","unstructured":"Linares L, Sanclemente G, Cervera C, Hoyo I, Cof\u00e1n F, Ricart MJ, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011;43:2145\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2011.05.007.","journal-title":"Transplant Proc"},{"key":"1847_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/tid.12247","volume":"16","author":"I Helanter\u00e4","year":"2014","unstructured":"Helanter\u00e4 I, Schachtner T, Hinrichs C, Salmela K, Kyll\u00f6nen L, Koskinen P, et al. Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis. 2014;16:568\u201377. https:\/\/doi.org\/10.1111\/tid.12247.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/tp.0000000000000832","volume":"100","author":"S Nagai","year":"2016","unstructured":"Nagai S, Mangus RS, Anderson E, Ekser B, Kubal CA, Fridell JA, et al. Cytomegalovirus infection after intestinal\/multivisceral transplantation: a single-center experience with 210 cases. Transplantation. 2016;100:451\u201360. https:\/\/doi.org\/10.1097\/tp.0000000000000832.","journal-title":"Transplantation"},{"key":"1847_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","volume":"13","author":"RR Razonable","year":"2013","unstructured":"Razonable RR, Humar A, The ASTIDCoP. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13:93\u2013106. https:\/\/doi.org\/10.1111\/ajt.12103.","journal-title":"Am J Transplant"},{"key":"1847_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11908-019-0699-0","volume":"21","author":"A Stern","year":"2019","unstructured":"Stern A, Papanicolaou GA. CMV prevention and treatment in transplantation: what\u2019s new in 2019. Curr Infect Dis Rep. 2019;21:45. https:\/\/doi.org\/10.1007\/s11908-019-0699-0.","journal-title":"Curr Infect Dis Rep"},{"key":"1847_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/tp.0000000000000160","volume":"98","author":"M Stern","year":"2014","unstructured":"Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98:1013\u20138. https:\/\/doi.org\/10.1097\/tp.0000000000000160.","journal-title":"Transplantation"},{"key":"1847_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/tp.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900\u201331. https:\/\/doi.org\/10.1097\/tp.0000000000002191.","journal-title":"Transplantation"},{"key":"1847_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","volume":"342","author":"EJ Ariza-Heredia","year":"2014","unstructured":"Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2013.09.004.","journal-title":"Cancer Lett"},{"key":"1847_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"N Cantoni","year":"2010","unstructured":"Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1309\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2010.03.020.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1847_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbmt.2014.10.004","volume":"21","author":"D Bhutani","year":"2015","unstructured":"Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, et al. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:159\u201364. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.004.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1847_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/tp.0000000000002024","volume":"102","author":"O Witzke","year":"2018","unstructured":"Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial. Transplantation. 2018;102:876\u201382. https:\/\/doi.org\/10.1097\/tp.0000000000002024.","journal-title":"Transplantation"},{"key":"1847_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/idr.S180908","volume":"12","author":"G El Helou","year":"2019","unstructured":"El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481\u201391. https:\/\/doi.org\/10.2147\/idr.S180908.","journal-title":"Infect Drug Resist"},{"key":"1847_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1399-0012.2008.00942.x","volume":"23","author":"L Danziger-Isakov","year":"2009","unstructured":"Danziger-Isakov L, Mark BG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant. 2009;23:295\u2013304. https:\/\/doi.org\/10.1111\/j.1399-0012.2008.00942.x.","journal-title":"Clin Transplant"},{"key":"1847_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5.","journal-title":"J Clin Epidemiol"},{"key":"1847_CR29","unstructured":"Deutsche stiftung organtransplantation. Jahresbericht: Organspende und transplantation in Deutschland 2020. 2020. https:\/\/dso.de\/SiteCollectionDocuments\/DSO-Jahresbericht%202020.pdf"},{"key":"1847_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/03007995.2019.1664827","volume":"36","author":"J Schelfhout","year":"2020","unstructured":"Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36:43\u201350. https:\/\/doi.org\/10.1080\/03007995.2019.1664827.","journal-title":"Curr Med Res Opin"},{"key":"1847_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12732","author":"Z Hakimi","year":"2017","unstructured":"Hakimi Z, Aball\u00e9a S, Ferchichi S, Scharn M, Odeyemi IA, Toumi M, et al. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis. 2017. https:\/\/doi.org\/10.1111\/tid.12732.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR32","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, et al. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin Infect Dis. 2020;71:2365\u201374. https:\/\/doi.org\/10.1093\/cid\/ciz1210.","journal-title":"Clin Infect Dis"},{"key":"1847_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jmii.2017.08.019","volume":"52","author":"L Wei","year":"2019","unstructured":"Wei L, Chen SJ, Huang SF, Chan YJ, Wang FD, Chen HP. Clinical significance of human cytomegalovirus viruria and the effect of antiviral therapy in hematopoietic stem cell transplant recipients. J Microbiol Immunol Infect. 2019;52:402\u20138. https:\/\/doi.org\/10.1016\/j.jmii.2017.08.019.","journal-title":"J Microbiol Immunol Infect"},{"key":"1847_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ctr.12288","volume":"28","author":"YV Smedbr\u00e5ten","year":"2014","unstructured":"Smedbr\u00e5ten YV, Sagedal S, Leivestad T, Mj\u00f8en G, Osnes K, Rollag H, et al. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant. 2014;28:120\u20136. https:\/\/doi.org\/10.1111\/ctr.12288.","journal-title":"Clin Transplant"},{"key":"1847_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1399-0012.2006.00639.x","volume":"21","author":"S Sagedal","year":"2007","unstructured":"Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant. 2007;21:309\u201313. https:\/\/doi.org\/10.1111\/j.1399-0012.2006.00639.x.","journal-title":"Clin Transplant"},{"key":"1847_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/00007890-199810270-00010","volume":"66","author":"ME Falagas","year":"1998","unstructured":"Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation. 1998;66:1020\u20138. https:\/\/doi.org\/10.1097\/00007890-199810270-00010.","journal-title":"Transplantation"},{"key":"1847_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7326\/0003-4819-126-4-199702150-00003","volume":"126","author":"ME Falagas","year":"1997","unstructured":"Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston center for liver transplantation CMVIG study group. Ann Intern Med. 1997;126:275\u20139. https:\/\/doi.org\/10.7326\/0003-4819-126-4-199702150-00003.","journal-title":"Ann Intern Med"},{"key":"1847_CR38","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bbmt.2015.01.011","volume":"21","author":"BK Au","year":"2015","unstructured":"Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, et al. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2015;21:848\u201354. https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.011.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1847_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciu364","volume":"59","author":"P Ljungman","year":"2014","unstructured":"Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473\u201381. https:\/\/doi.org\/10.1093\/cid\/ciu364.","journal-title":"Clin Infect Dis"},{"key":"1847_CR40","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1097\/tp.0000000000000641","volume":"99","author":"R Desai","year":"2015","unstructured":"Desai R, Collett D, Watson CJ, Johnson PJ, Moss P, Neuberger J. Impact of cytomegalovirus on long-term mortality and cancer risk after organ transplantation. Transplantation. 2015;99:1989\u201394. https:\/\/doi.org\/10.1097\/tp.0000000000000641.","journal-title":"Transplantation"},{"key":"1847_CR41","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/jocs.14588","volume":"35","author":"A Suarez-Pierre","year":"2020","unstructured":"Suarez-Pierre A, Giuliano K, Lui C, Almaguer D, Etchill E, Choi CW, et al. Impact of cytomegalovirus serologic status on heart transplantation. J Card Surg. 2020;35:1431\u20138. https:\/\/doi.org\/10.1111\/jocs.14588.","journal-title":"J Card Surg"},{"key":"1847_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12964","volume":"20","author":"C Mabilangan","year":"2018","unstructured":"Mabilangan C, Preiksaitis J, Cervera C. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Transpl Infect Dis. 2018;20: e12964. https:\/\/doi.org\/10.1111\/tid.12964.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13015","volume":"21","author":"C Mabilangan","year":"2019","unstructured":"Mabilangan C, Preiksaitis JK, Cervera C. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Transpl Infect Dis. 2019;21: e13015. https:\/\/doi.org\/10.1111\/tid.13015.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12873","volume":"20","author":"M Serrano-Alonso","year":"2018","unstructured":"Serrano-Alonso M, Guillen-Grima F, Martin-Moreno P, Rabago G, Manrique J, Garcia-Del-Barrio M, et al. Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation. Transpl Infect Dis. 2018;20: e12873. https:\/\/doi.org\/10.1111\/tid.12873.","journal-title":"Transpl Infect Dis"},{"key":"1847_CR45","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/cid\/ciz490","volume":"70","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70:1525\u201333. https:\/\/doi.org\/10.1093\/cid\/ciz490.","journal-title":"Clin Infect Dis"},{"key":"1847_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","volume":"56","author":"Y Mori","year":"2021","unstructured":"Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56:853\u201362. https:\/\/doi.org\/10.1038\/s41409-020-01082-z.","journal-title":"Bone Marrow Transplant"},{"key":"1847_CR47","unstructured":"Committee for medicinal products for human Use (CHMP). Clinical investigation of immunosuppressants for solid organ transplantation. European medicines agency; 2009. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-immunosuppressants-solid-organ-transplantation_en.pdf"},{"key":"1847_CR48","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/ajt.15480","volume":"19","author":"SP Berger","year":"2019","unstructured":"Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019;19:3018\u201334. https:\/\/doi.org\/10.1111\/ajt.15480.","journal-title":"Am J Transplant"},{"key":"1847_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00362","author":"S Masouridi-Levrat","year":"2016","unstructured":"Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016. https:\/\/doi.org\/10.3389\/fimmu.2016.00362.","journal-title":"Front Immunol"},{"key":"1847_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1491-2_1","volume-title":"Fluid and electrolyte disorders associated with orthotopic liver transplantation","author":"AH Wilkinson","year":"1990","unstructured":"Wilkinson AH, Danovitch G, Mischel M. Fluid and electrolyte disorders associated with orthotopic liver transplantation. Springer; 1990. https:\/\/doi.org\/10.1007\/978-1-4613-1491-2_1"},{"key":"1847_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fmed.2018.00261","volume":"5","author":"V Pochineni","year":"2018","unstructured":"Pochineni V, Rondon-Berrios H. Electrolyte and acid-base disorders in the renal transplant recipient. Front Med (Lausanne). 2018;5:261. https:\/\/doi.org\/10.3389\/fmed.2018.00261.","journal-title":"Front Med (Lausanne)"},{"key":"1847_CR52","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.bbmt.2017.08.021","volume":"23","author":"G Rond\u00f3n","year":"2017","unstructured":"Rond\u00f3n G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, et al. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23:2166\u201371. https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.021.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1847_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13866","volume":"34","author":"A Anderson","year":"2020","unstructured":"Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J. Clinical, \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020;34: e13866. https:\/\/doi.org\/10.1111\/ctr.13866.","journal-title":"Clin Transplant"},{"key":"1847_CR54","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","volume":"100","author":"P Derigs","year":"2021","unstructured":"Derigs P, Radujkovic A, Schubert ML, Schnitzler P, Sch\u00f6ning T, M\u00fcller-Tidow C, et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol. 2021;100:2087\u201393. https:\/\/doi.org\/10.1007\/s00277-020-04362-2.","journal-title":"Ann Hematol"},{"key":"1847_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","volume":"73","author":"HN Imlay","year":"2021","unstructured":"Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021;73:156\u201360. https:\/\/doi.org\/10.1093\/cid\/ciaa1713.","journal-title":"Clin Infect Dis"},{"key":"1847_CR56","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","volume":"381","author":"J Maertens","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, Poir\u00e9 X, Uknis M, Wu J, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381:1136\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1714656.","journal-title":"N Engl J Med"},{"key":"1847_CR57","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1128\/aac.47.4.1334-1342.2003","volume":"47","author":"LH Wang","year":"2003","unstructured":"Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47:1334\u201342. https:\/\/doi.org\/10.1128\/aac.47.4.1334-1342.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1847_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988","author":"RK Avery","year":"2021","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clinical Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab988.","journal-title":"Clinical Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01847-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T02:46:18Z","timestamp":1669689978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01847-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01847-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT received honoraria and travel grants from ACI Clinical, BioNTech, Gilead, F2G, iQone, MSD, Octapharma, Pfizer, and Takeda, received travel grants from AbbVie, Astellas, Celgene, Jazz, and Medac, serves as a consultant for ACI Clinical, BioNTech, Gilead, iQone, MSD, Octapharma, Pfizer, and Takeda, and received research grants from Gilead. JK is an employee of Takeda Pharma Vertrieb GmbH & Co.\u00a0KG. CP is an employee of Takeda Pharma Vertrieb GmbH & Co. KG and owner of Takeda shares. SJ is an employee of Ingress-Health HWM GmbH, a wholly owned subsidiary of Cytel Inc., contracted by Takeda Pharma Vertrieb GmbH & Co. KG to conduct this research. OW received research grants for clinical studies, speaker\u2019s fees, honoraria, and travel expenses from Alexion, Amgen, Astellas, Basilea, Biotest, Bristol Myers Squibb, Chiesi, Correvio, Gilead, Hexal, Janssen, Dr. F. K\u00f6hler Chemie, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, Takeda, Teva, and UCB, as well as an Unrestricted grant of the Rudolf-Ackermann-Stiftung (Stiftung f\u00fcr Klinische Infektiologie).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"As the dataset was anonymized, no ethical approval and no informed consent of patients was required. The study protocol was reviewed by the data owner (AOK PLUS), who subsequently approved the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}